1 – 147 of 147
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Non-Motor Symptom Management : Insights into Adherence to Treatment Guidelines in Parkinson’s Disease Patients
(
- Contribution to journal › Article
-
Mark
Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion
2024) In Movement Disorders Clinical Practice(
- Contribution to journal › Article
-
Mark
The Care Needs of Patients With Cognitive Impairment in Late-Stage Parkinson’s Disease
2024) In Journal of Geriatric Psychiatry and Neurology(
- Contribution to journal › Article
-
Mark
Meaning in Life in Late-Stage Parkinson’s Disease : Results from the Care of Late-Stage Parkinsonism Study (CLaSP) in Six European Countries
(
- Contribution to journal › Article
-
Mark
A systematic practice review : Providing palliative care for people with Parkinson’s disease and their caregivers
(
- Contribution to journal › Scientific review
-
Mark
Factors associated with self-rated health in people with late-stage parkinson’s and cognitive impairment
2024) In Quality of Life Research(
- Contribution to journal › Article
-
Mark
Economic Burden of Parkinson’s Disease : A Multinational, Real-World, Cost-of-Illness Study
2024) In Drugs - Real World Outcomes(
- Contribution to journal › Article
-
Mark
Care of Late-Stage Parkinsonism : Resource Utilization of the Disease in Five European Countries
(
- Contribution to journal › Article
- 2023
-
Mark
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
The Relationship between PDQ-8 and Costs in Parkinson's Disease—A Swedish Register-Based Study
(
- Contribution to journal › Article
-
Mark
Time to workforce exit after a Parkinson's disease diagnosis
(
- Contribution to journal › Article
-
Mark
Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(
- Contribution to journal › Scientific review
-
Mark
A Paradigm Shift in the Management of Patients with Parkinson's Disease
(
- Contribution to journal › Scientific review
-
Mark
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
(
- Contribution to journal › Scientific review
-
Mark
Agreement between Parkinson Disease Home Diary and Observer Assessments before and after Structured Patient Training
(
- Contribution to journal › Article
-
Mark
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
(
- Contribution to journal › Article
-
Mark
Agreement Between Parkinson Disease Home Diary and Observer Assessments Before and After Structured Patient Training
2023) 2023 International Congress of The Parkinson and Movement Disorder Society(
- Contribution to conference › Abstract
-
Mark
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life
(
- Contribution to journal › Article
-
Mark
Application of single wrist-wearable accelerometry for objective motor diary assessment in fluctuating Parkinson's disease
(
- Contribution to journal › Article
-
Mark
The Impact of COVID-19 on Parkinson's Disease : A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients' Perceptions
(
- Contribution to journal › Article
-
Mark
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
2023) In European Journal of Neurology(
- Contribution to journal › Article
-
Mark
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum : Revelations from the MANAGE-PD validation cohort
(
- Contribution to journal › Article
-
Mark
Levodopa Dose Equivalency in Parkinson's Disease : Updated Systematic Review and Proposals
(
- Contribution to journal › Article
- 2022
-
Mark
Diagnostic work up : Laboratory and biomarkers
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
Gait and balance among people with de novo vs. mild to moderate Parkinson’s disease
2022) 6th International Conference on Neurology and Brain Disorders (Virtual)(
- Contribution to conference › Abstract
-
Mark
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(
- Contribution to journal › Article
-
Mark
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
(
- Contribution to journal › Article
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
(
- Contribution to journal › Article
-
Mark
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
(
- Contribution to journal › Scientific review
-
Mark
Caregiver Burden in Late-Stage Parkinsonism and Its Associations
(
- Contribution to journal › Article
-
Mark
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
High risk of developing dementia in Parkinson’s disease : a Swedish registry-based study
(
- Contribution to journal › Article
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
-
Mark
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep : Results from a Meta-Analysis with 24-Month Follow-Up
(
- Contribution to journal › Scientific review
-
Mark
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease : A Systematic Review and Bayesian Network Meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
(
- Contribution to journal › Article
-
Mark
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease : Real-World Evidence From G7 Countries
(
- Contribution to journal › Article
- 2021
-
Mark
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease : A Swedish Register-Based Study in 1823 Observations
(
- Contribution to journal › Article
-
Mark
Longitudinal prediction of falls and near falls frequencies in Parkinson's disease:a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Parkinson’s disease in Sweden—resource use and costs by severity
(
- Contribution to journal › Article
-
Mark
Clinical Usefulness of Retropulsion Tests in Persons with Mild to Moderate Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Perspectives on Care for Late-Stage Parkinson's Disease
(
- Contribution to journal › Scientific review
-
Mark
Close relationships in Parkinson´s disease patients with device-aided therapy
(
- Contribution to journal › Article
-
Mark
Swedish guidelines for device-aided therapies in Parkinson's disease —Economic evaluation and implementation
(
- Contribution to journal › Article
-
Mark
Factors Associated with Health-Related Quality of Life in Late-Stage Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
The Non-Motor Symptoms Scale in Parkinson’s disease : Validation and use
(
- Contribution to journal › Scientific review
-
Mark
Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease : A Structured Review
(
- Contribution to journal › Scientific review
-
Mark
Characteristics of Patients with Late-Stage Parkinsonism who are Nursing Home Residents Compared with those Living at Home
(
- Contribution to journal › Article
-
Mark
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Digital health technology for non-motor symptoms in people with Parkinson's disease : Futile or future?
(
- Contribution to journal › Scientific review
-
Mark
Parkinson's Disease and Post–COVID-19 Syndrome : The Parkinson's Long-COVID Spectrum
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers—Study Protocol for a Multicentre, Randomized Controlled Trial
(
- Contribution to journal › Article
-
Mark
Personalised advanced therapies in parkinson’s disease : The role of non-motor symptoms profile
(
- Contribution to journal › Article
-
Mark
Validation and clinical value of the MANAGE-PD tool : A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications
(
- Contribution to journal › Article
- 2020
-
Mark
Levodopa infusion in Parkinson's disease : Individual quality of life
(
- Contribution to journal › Article
-
Mark
Everyday Occupations and Other Factors in Relation to Mental Well-Being among Persons with Advanced Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Parkinsons sjukdom – heterogen och komplex i sitt kliniska uttryck - Individuella kombinationer av symtom som ändrar sig över tid kräver behandlingsjusteringar och anpassningar
(
- Contribution to journal › Article
-
Mark
Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis : The COVID-19 Experience
(
- Contribution to journal › Scientific review
-
Mark
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia
(
- Contribution to journal › Article
-
Mark
The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism
(
- Contribution to journal › Article
-
Mark
Optimizing Treatment in Undertreated Late-Stage Parkinsonism : A Pragmatic Randomized Trial
(
- Contribution to journal › Article
-
Mark
Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia
(
- Contribution to journal › Article
- 2019
-
Mark
Disease stage dependency of motor and non-motor fluctuations in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Satisfaction with care in late stage Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Low prevalence of known pathogenic mutations in dominant PD genes : A Swedish multicenter study
(
- Contribution to journal › Article
-
Mark
EuroInf 2 : Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
2019) In Movement Disorders(
- Contribution to journal › Article
- 2018
-
Mark
Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
Levodopa effect and motor function in late stage Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Dopaminergic effect on non-motor symptoms in late stage Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Reduced workforce participation 5 years prior to first Parkinson’s disease sick-leave
(
- Contribution to journal › Article
-
Mark
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
(
- Contribution to journal › Article
-
Mark
Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study
(
- Contribution to journal › Article
-
Mark
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease : a multi-country Delphi-panel approach
(
- Contribution to journal › Article
-
Mark
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Etiology and pathogenesis of parkinson’s disease
2017) p.95-101(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale for use in Sweden
2017) 21st International Congress of Parkinson's Disease and Movement Disorders(
- Contribution to conference › Abstract
-
Mark
Factors associated with perceived walking difficulties in people with Parkinson’s disease
(
- Contribution to journal › Published meeting abstract
-
Mark
Device-Aided Treatment Strategies in Advanced Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Factors associated with perceived walking difficulties in people with Parkinson’s disease
2017) 21st International Congress of Parkinson's Disease and Movement Disorders(
- Contribution to conference › Abstract
-
Mark
Factors Contributing to Perceived Walking Difficulties in People with Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Levodopa effect and motor function in late stage Parkinson’s disease
(
- Contribution to conference › Abstract
-
Mark
Workforce unavailability in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale
(
- Contribution to journal › Article
-
Mark
Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
(
- Contribution to journal › Scientific review
-
Mark
Levodopa-carbidopa intestinal gel in advanced Parkinson's : Final results of the GLORIA registry
(
- Contribution to journal › Article
-
Mark
A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement
(
- Contribution to journal › Article
- 2016
-
Mark
Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Oral and infusion levodopa therapy in the management of Parkinson’s disease
2016) p.63-75(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease : For Whom, When, and How?
(
- Contribution to journal › Scientific review
-
Mark
Continuous dopaminergic stimulation therapy for Parkinson's disease - Recent advances
(
- Contribution to journal › Article
-
Mark
Fall-related activity avoidance in relation to a history of falls or near falls, fear of falling and disease severity in people with Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Perceived walking difficulties in relation to motor aspects in Parkinson’s disease
2016) 4th World Parkinson Congress(
- Contribution to conference › Abstract
-
Mark
Life satisfaction in Parkinson's disease - associated factors
2016) The 20th International Congress of Parkinson's Disease and Movement Disorders(
- Contribution to conference › Abstract
-
Mark
Non-oral dopaminergic therapies for Parkinson's disease : current treatments and the future
(
- Contribution to journal › Scientific review
-
Mark
Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Integrated Safety of Levodopa-Carbidopa Intestinal Gel From Prospective Clinical Trials.
(
- Contribution to journal › Article
- 2015
-
Mark
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany
(
- Contribution to journal › Article
-
Mark
Fall-related activity avoidance in people ageing with Parkinson’s disease
2015) 68th Annual Scientific Meeting of the Gerontological Society of America(
- Contribution to conference › Abstract
-
Mark
Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease.
2015) In Acta Neurologica Scandinavica(
- Contribution to journal › Article
-
Mark
The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
(
- Contribution to journal › Article
-
Mark
Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease.
(
- Contribution to journal › Article
-
Mark
Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS)
(
- Contribution to journal › Article
-
Mark
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
(
- Contribution to journal › Scientific review
-
Mark
King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation.
(
- Contribution to journal › Article
-
Mark
The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system.
(
- Contribution to journal › Article
-
Mark
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Final 12-Month, Open-Label Results
(
- Contribution to journal › Article
-
Mark
EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study.
(
- Contribution to journal › Article
-
Mark
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
(
- Contribution to journal › Article
- 2013
-
Mark
Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients
(
- Contribution to journal › Article
-
Mark
Reduced Body Mass Index in Parkinson's Disease: Contribution of Comorbid Depression.
(
- Contribution to journal › Article
-
Mark
A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need
(
- Contribution to journal › Article
-
Mark
Nonmotor fluctuations in Parkinson disease: Severity and correlation with motor complications.
(
- Contribution to journal › Article
-
Mark
Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care
(
- Contribution to journal › Article
-
Mark
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
(
- Contribution to journal › Article
- 2012
-
Mark
Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects.
(
- Contribution to journal › Article
-
Mark
Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease
(
- Contribution to journal › Article
-
Mark
Gender-related differences in the burden of non-motor symptoms in Parkinson's disease
(
- Contribution to journal › Article
- 2011
-
Mark
Levodopa--carbidopa intestinal gel for treatment of advanced Parkinson''s disease
(
- Contribution to journal › Scientific review
-
Mark
What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?
(
- Contribution to journal › Article
-
Mark
Wirkung von Apomorphin auf nicht motorische Symptome bei Morbus Parkinson
(
- Contribution to journal › Scientific review
-
Mark
Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Apomorphininjektionstherapie bei Morbus Parkinson
(
- Contribution to journal › Scientific review
-
Mark
Drug-related problems in Parkinson's disease: the role of community pharmacists in primary care
(
- Contribution to journal › Article
-
Mark
Parkinson's disease: The non-motor issues
(
- Contribution to journal › Scientific review
-
Mark
Apomorphin zur subkutanen Dauerinfusion bei fortgeschrittenem Morbus Parkinson: Effektivität, Verträglichkeit und Patientenzufriedenheit im Langzeitverlauf
(
- Contribution to journal › Scientific review
- 2010
-
Mark
The challenge of non-motor symptoms in Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
Non-motor Symptoms Questionnaire and Scale for Parkinson's disease
(
- Contribution to journal › Article
- 2009
-
Mark
Dopamine replacement therapy in Parkinson´s Disease: past, present and future
2009) p.309-334(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2000
-
Mark
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
(
- Contribution to journal › Article
- 1999
-
Mark
Sequential bilateral transplantation in Parkinson's disease: effects of the second graft
(
- Contribution to journal › Article
- 1997
-
Mark
Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease
(
- Contribution to journal › Article
- 1996
-
Mark
Effects of brain-derived neurotrophic factor on neuronal structure of dopaminergic neurons in dissociated cultures of human fetal mesencephalon
(
- Contribution to journal › Article
- 1995
-
Mark
Protective effects of BDNF and NT-3 but not PDGF against hypoglycemic injury to cultured striatal neurons
(
- Contribution to journal › Article
- 1994
-
Mark
Depression vanlig vid Parkinsons sjukdom. Begränsade studier kring symtom och behandling
(
- Contribution to journal › Article
- 1993
-
Mark
Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture
(
- Contribution to journal › Article
-
Mark
Expression of platelet-derived growth factor in and around intrastriatal embryonic mesencephalic grafts
(
- Contribution to journal › Article
- 1986
-
Mark
Chemical characterization of cell-CAM 105, a cell-adhesion molecule isolated from rat liver membranes
(
- Contribution to journal › Article